TITLE:
Iressa Expanded Access Program (EAP)

CONDITION:
Carcinoma

INTERVENTION:
ZD1839 (Gefitinib)

SUMMARY:

      A program for patients with non small cell lung cancer who may benefit from Iressa, but
      cannot enter another clinical trial due to them not being eligible, or for whom no trials
      are available.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        For inclusion in this trial, patients must fulfill all of the following criteria:

          -  previous documented histologically or cytologically confirmed non-small cell lung
             cancer;

          -  locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III
             or IV)patients who have received at least one course of standard systemic
             chemotherapy or radiation therapy or are ineligible for chemotherapy or radiotherapy
             or are ineligible or not a candidate for enrollment on another ZD1839 trial or who,
             in the Investigator's opinion, are not medically suitable for chemotherapy.

          -  age 18 years or older;

          -  written informed consent to participate in the trial.

        Exclusion Criteria

        Any of the following will exclude a patient from entering the trial:

          -  receiving concurrent radiotherapy, chemotherapy, or other systemic anti-cancer
             medication or any other investigational agent. * Non-cytotoxic or hormonal therapies
             for the adjuvant treatment of cancer or for previously treated cancers may be allowed
             per AstraZeneca permission;

          -  patients eligible for or previously enrolled on a ZD1839 blinded clinical trial
             protocol. Patients eligible for or previously enrolled on an open-label or unblinded
             ZD1839 clinical trial may be considered for acceptance into the Expanded Access
             Program with AstraZeneca permission;

          -  having other active malignancies;

          -  incomplete healing from previous oncologic or other major surgery;

          -  evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the patient to participate in the trial;

          -  pregnancy or breast feeding (women of child-bearing potential).
      
